Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50


A machine learning approach for somatic mutation discovery.

Wood DE, White JR, Georgiadis A, Van Emburgh B, Parpart-Li S, Mitchell J, Anagnostou V, Niknafs N, Karchin R, Papp E, McCord C, LoVerso P, Riley D, Diaz LA Jr, Jones S, Sausen M, Velculescu VE, Angiuoli SV.

Sci Transl Med. 2018 Sep 5;10(457). pii: eaar7939. doi: 10.1126/scitranslmed.aar7939.


Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer.

Boudadi K, Suzman DL, Anagnostou V, Fu W, Luber B, Wang H, Niknafs N, White JR, Silberstein JL, Sullivan R, Dowling D, Harb R, Nirschl TR, Veeneman BA, Tomlins SA, Wang Y, Jendrisak A, Graf RP, Dittamore R, Carducci MA, Eisenberger MA, Haffner MC, Meeker AK, Eshleman JR, Luo J, Velculescu VE, Drake CG, Antonarakis ES.

Oncotarget. 2018 Jun 19;9(47):28561-28571. doi: 10.18632/oncotarget.25564. eCollection 2018 Jun 19.


Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC).

Cottrell TR, Thompson ED, Forde PM, Stein JE, Duffield AS, Anagnostou V, Rekhtman N, Anders RA, Cuda JD, Illei PB, Gabrielson E, Askin FB, Niknafs N, Smith KN, Velez MJ, Sauter JL, Isbell JM, Jones DR, Battafarano RJ, Yang SC, Danilova L, Wolchok JD, Topalian SL, Velculescu VE, Pardoll DM, Brahmer JR, Hellmann MD, Chaft JE, Cimino-Mathews A, Taube JM.

Ann Oncol. 2018 Aug 1;29(8):1853-1860. doi: 10.1093/annonc/mdy218.


The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity.

Danilova L, Anagnostou V, Caushi JX, Sidhom JW, Guo H, Chan HY, Suri P, Tam A, Zhang J, Asmar ME, Marrone KA, Naidoo J, Brahmer JR, Forde PM, Baras AS, Cope L, Velculescu VE, Pardoll DM, Housseau F, Smith KN.

Cancer Immunol Res. 2018 Aug;6(8):888-899. doi: 10.1158/2326-6066.CIR-18-0129. Epub 2018 Jun 12.


Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.

Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, Zahurak M, Yang SC, Jones DR, Broderick S, Battafarano RJ, Velez MJ, Rekhtman N, Olah Z, Naidoo J, Marrone KA, Verde F, Guo H, Zhang J, Caushi JX, Chan HY, Sidhom JW, Scharpf RB, White J, Gabrielson E, Wang H, Rosner GL, Rusch V, Wolchok JD, Merghoub T, Taube JM, Velculescu VE, Topalian SL, Brahmer JR, Pardoll DM.

N Engl J Med. 2018 May 24;378(21):1976-1986. doi: 10.1056/NEJMoa1716078. Epub 2018 Apr 16.


Primary parotid adenocarcinoma metastasis to the spleen with PIK3CA mutation: cytological findings and review of the literature.

Inouye CM, Anagnostou V, Li QK.

Int J Clin Exp Pathol. 2017;10(5):5999-6005. Epub 2017 May 15. Review.


Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer.

Topper MJ, Vaz M, Chiappinelli KB, DeStefano Shields CE, Niknafs N, Yen RC, Wenzel A, Hicks J, Ballew M, Stone M, Tran PT, Zahnow CA, Hellmann MD, Anagnostou V, Strissel PL, Strick R, Velculescu VE, Baylin SB.

Cell. 2017 Nov 30;171(6):1284-1300.e21. doi: 10.1016/j.cell.2017.10.022.


Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity.

Anagnostou V, Yarchoan M, Hansen AR, Wang H, Verde F, Sharon E, Collyar D, Chow LQM, Forde PM.

Clin Cancer Res. 2017 Sep 1;23(17):4959-4969. doi: 10.1158/1078-0432.CCR-16-3065.


Direct detection of early-stage cancers using circulating tumor DNA.

Phallen J, Sausen M, Adleff V, Leal A, Hruban C, White J, Anagnostou V, Fiksel J, Cristiano S, Papp E, Speir S, Reinert T, Orntoft MW, Woodward BD, Murphy D, Parpart-Li S, Riley D, Nesselbush M, Sengamalay N, Georgiadis A, Li QK, Madsen MR, Mortensen FV, Huiskens J, Punt C, van Grieken N, Fijneman R, Meijer G, Husain H, Scharpf RB, Diaz LA Jr, Jones S, Angiuoli S, ├śrntoft T, Nielsen HJ, Andersen CL, Velculescu VE.

Sci Transl Med. 2017 Aug 16;9(403). pii: eaan2415. doi: 10.1126/scitranslmed.aan2415.


Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.

Anagnostou V, Smith KN, Forde PM, Niknafs N, Bhattacharya R, White J, Zhang T, Adleff V, Phallen J, Wali N, Hruban C, Guthrie VB, Rodgers K, Naidoo J, Kang H, Sharfman W, Georgiades C, Verde F, Illei P, Li QK, Gabrielson E, Brock MV, Zahnow CA, Baylin SB, Scharpf RB, Brahmer JR, Karchin R, Pardoll DM, Velculescu VE.

Cancer Discov. 2017 Mar;7(3):264-276. doi: 10.1158/2159-8290.CD-16-0828. Epub 2016 Dec 28.


The genomic landscape of response to EGFR blockade in colorectal cancer.

Bertotti A, Papp E, Jones S, Adleff V, Anagnostou V, Lupo B, Sausen M, Phallen J, Hruban CA, Tokheim C, Niknafs N, Nesselbush M, Lytle K, Sassi F, Cottino F, Migliardi G, Zanella ER, Ribero D, Russolillo N, Mellano A, Muratore A, Paraluppi G, Salizzoni M, Marsoni S, Kragh M, Lantto J, Cassingena A, Li QK, Karchin R, Scharpf R, Sartore-Bianchi A, Siena S, Diaz LA Jr, Trusolino L, Velculescu VE.

Nature. 2015 Oct 8;526(7572):263-7. doi: 10.1038/nature14969. Epub 2015 Sep 30.


Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients.

Sausen M, Phallen J, Adleff V, Jones S, Leary RJ, Barrett MT, Anagnostou V, Parpart-Li S, Murphy D, Kay Li Q, Hruban CA, Scharpf R, White JR, O'Dwyer PJ, Allen PJ, Eshleman JR, Thompson CB, Klimstra DS, Linehan DC, Maitra A, Hruban RH, Diaz LA Jr, Von Hoff DD, Johansen JS, Drebin JA, Velculescu VE.

Nat Commun. 2015 Jul 7;6:7686. doi: 10.1038/ncomms8686.


Personalized genomic analyses for cancer mutation discovery and interpretation.

Jones S, Anagnostou V, Lytle K, Parpart-Li S, Nesselbush M, Riley DR, Shukla M, Chesnick B, Kadan M, Papp E, Galens KG, Murphy D, Zhang T, Kann L, Sausen M, Angiuoli SV, Diaz LA Jr, Velculescu VE.

Sci Transl Med. 2015 Apr 15;7(283):283ra53. doi: 10.1126/scitranslmed.aaa7161.


Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer.

Anagnostou VK, Brahmer JR.

Clin Cancer Res. 2015 Mar 1;21(5):976-84. doi: 10.1158/1078-0432.CCR-14-1187. Review.


Preanalytical variables and phosphoepitope expression in FFPE tissue: quantitative epitope assessment after variable cold ischemic time.

Vassilakopoulou M, Parisi F, Siddiqui S, England AM, Zarella ER, Anagnostou V, Kluger Y, Hicks DG, Rimm DL, Neumeister VM.

Lab Invest. 2015 Mar;95(3):334-41. doi: 10.1038/labinvest.2014.139. Epub 2014 Nov 24.


A longitudinal, collaborative, practice-based learning and improvement model to improve post-discharge heart failure outcomes.

Anagnostou VK, Bailey G, Sze E, Hay S, Hyson A, Federman DG.

Conn Med. 2014 Jan;78(1):33-6.


A tissue quality index: an intrinsic control for measurement of effects of preanalytical variables on FFPE tissue.

Neumeister VM, Parisi F, England AM, Siddiqui S, Anagnostou V, Zarrella E, Vassilakopolou M, Bai Y, Saylor S, Sapino A, Kluger Y, Hicks DG, Bussolati G, Kwei S, Rimm DL.

Lab Invest. 2014 Apr;94(4):467-74. doi: 10.1038/labinvest.2014.7. Epub 2014 Feb 17.


Programmed death ligand-1 expression in non-small cell lung cancer.

Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, Herbst RS, Gettinger SN, Chen L, Rimm DL.

Lab Invest. 2014 Jan;94(1):107-16. doi: 10.1038/labinvest.2013.130. Epub 2013 Nov 11.


Seroprevalence of Toscana virus among residents of Aegean Sea islands, Greece.

Anagnostou V, Papa A.

Travel Med Infect Dis. 2013 Mar-Apr;11(2):98-102. doi: 10.1016/j.tmaid.2012.11.006. Epub 2013 Jan 9.


Quantitative assessment of effect of preanalytic cold ischemic time on protein expression in breast cancer tissues.

Neumeister VM, Anagnostou V, Siddiqui S, England AM, Zarrella ER, Vassilakopoulou M, Parisi F, Kluger Y, Hicks DG, Rimm DL.

J Natl Cancer Inst. 2012 Dec 5;104(23):1815-24. doi: 10.1093/jnci/djs438. Epub 2012 Oct 22.


Measurement of aldehyde dehydrogenase 1 expression defines a group with better prognosis in patients with non-small cell lung cancer.

Dimou A, Neumeister V, Agarwal S, Anagnostou V, Syrigos K, Rimm DL.

Am J Pathol. 2012 Oct;181(4):1436-42. doi: 10.1016/j.ajpath.2012.06.037. Epub 2012 Aug 8.


Prevalence of antibodies to phleboviruses within the sand fly fever Naples virus species in humans, northern Greece.

Anagnostou V, Papa A.

Clin Microbiol Infect. 2013 Jun;19(6):566-70. doi: 10.1111/j.1469-0691.2012.03957.x. Epub 2012 Jul 6.


Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells.

Zito CR, Jilaveanu LB, Anagnostou V, Rimm D, Bepler G, Maira SM, Hackl W, Camp R, Kluger HM, Chao HH.

PLoS One. 2012;7(2):e31331. doi: 10.1371/journal.pone.0031331. Epub 2012 Feb 15.


Mechanisms in endocrinology: primary HT and risk for breast cancer: a systematic review and meta-analysis.

Angelousi AG, Anagnostou VK, Stamatakos MK, Georgiopoulos GA, Kontzoglou KC.

Eur J Endocrinol. 2012 Mar;166(3):373-81. doi: 10.1530/EJE-11-0838. Epub 2011 Oct 24. Review.


Molecular classification of nonsmall cell lung cancer using a 4-protein quantitative assay.

Anagnostou VK, Dimou AT, Botsis T, Killiam EJ, Gustavson MD, Homer RJ, Boffa D, Zolota V, Dougenis D, Tanoue L, Gettinger SN, Detterbeck FC, Syrigos KN, Bepler G, Rimm DL.

Cancer. 2012 Mar 15;118(6):1607-18. doi: 10.1002/cncr.26450. Epub 2011 Aug 25.


Distribution of sandflies (Diptera, Psychodidae) in two Ionian Islands and northern Greece.

Xanthopoulou K, Anagnostou V, Ivovic V, Djurkovic-Djakovic O, Rogozi E, Sotiraki S, Papa A.

Vector Borne Zoonotic Dis. 2011 Dec;11(12):1591-4. doi: 10.1089/vbz.2011.0750. Epub 2011 Sep 15.


Standardization of epidermal growth factor receptor (EGFR) measurement by quantitative immunofluorescence and impact on antibody-based mutation detection in non-small cell lung cancer.

Dimou A, Agarwal S, Anagnostou V, Viray H, Christensen S, Gould Rothberg B, Zolota V, Syrigos K, Rimm DL.

Am J Pathol. 2011 Aug;179(2):580-9. doi: 10.1016/j.ajpath.2011.04.031. Epub 2011 Jun 12.


Novel phlebovirus in febrile child, Greece.

Anagnostou V, Pardalos G, Athanasiou-Metaxa M, Papa A.

Emerg Infect Dis. 2011 May;17(5):940-1. doi: 10.3201/eid1705.101958. No abstract available.


Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study.

Osborne CK, Neven P, Dirix LY, Mackey JR, Robert J, Underhill C, Schiff R, Gutierrez C, Migliaccio I, Anagnostou VK, Rimm DL, Magill P, Sellers M.

Clin Cancer Res. 2011 Mar 1;17(5):1147-59. doi: 10.1158/1078-0432.CCR-10-1869. Epub 2011 Jan 10.


Multiplexed analysis of angiogenesis and lymphangiogenesis factors predicts outcome for non-small cell lung cancer patients.

Anagnostou VK, Tiniakos DG, Fotinou M, Achimastos A, Syrigos KN.

Virchows Arch. 2011 Mar;458(3):331-40. doi: 10.1007/s00428-010-1015-4. Epub 2010 Dec 14.


Phlebovirus meningoencephalis complicated by Pseudomonas aeruginosa pneumonia: a case report.

Anagnostou V, Sdouga M, Volakli H, Violaki A, Papa A.

Vector Borne Zoonotic Dis. 2011 May;11(5):595-6. doi: 10.1089/vbz.2010.0041. Epub 2010 Jun 24.


Modeling prognostic factors in resectable pancreatic adenocarcinomas.

Botsis T, Anagnostou VK, Hartvigsen G, Hripcsak G, Weng C.

Cancer Inform. 2010 Jan 20;7:281-91.


High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology.

Anagnostou VK, Lowery FJ, Zolota V, Tzelepi V, Gopinath A, Liceaga C, Panagopoulos N, Frangia K, Tanoue L, Boffa D, Gettinger S, Detterbeck F, Homer RJ, Dougenis D, Rimm DL, Syrigos KN.

BMC Cancer. 2010 May 9;10:186. doi: 10.1186/1471-2407-10-186.


Differential sensitivity to platinum-based chemotherapy in primary uterine serous papillary carcinoma cell lines with high vs low HER-2/neu expression in vitro.

Cross SN, Cocco E, Bellone S, Anagnostou VK, Brower SL, Richter CE, Siegel ER, Schwartz PE, Rutherford TJ, Santin AD.

Am J Obstet Gynecol. 2010 Aug;203(2):162.e1-8. doi: 10.1016/j.ajog.2010.02.056. Epub 2010 Apr 24.


Quantitative evaluation of protein expression as a function of tissue microarray core diameter: is a large (1.5 mm) core better than a small (0.6 mm) core?

Anagnostou VK, Lowery FJ, Syrigos KN, Cagle PT, Rimm DL.

Arch Pathol Lab Med. 2010 Apr;134(4):613-9. doi: 10.1043/1543-2165-134.4.613.


Antibody validation.

Bordeaux J, Welsh A, Agarwal S, Killiam E, Baquero M, Hanna J, Anagnostou V, Rimm D.

Biotechniques. 2010 Mar;48(3):197-209. doi: 10.2144/000113382. Review. Erratum in: Biotechniques. 2010 May;48(5):351.


Analytic variability in immunohistochemistry biomarker studies.

Anagnostou VK, Welsh AW, Giltnane JM, Siddiqui S, Liceaga C, Gustavson M, Syrigos KN, Reiter JL, Rimm DL.

Cancer Epidemiol Biomarkers Prev. 2010 Apr;19(4):982-91. doi: 10.1158/1055-9965.EPI-10-0097. Epub 2010 Mar 23.


Evolution of Crimean-Congo Hemorrhagic Fever virus.

Anagnostou V, Papa A.

Infect Genet Evol. 2009 Sep;9(5):948-54. doi: 10.1016/j.meegid.2009.06.018. Epub 2009 Jun 26.


GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer.

Scott KL, Kabbarah O, Liang MC, Ivanova E, Anagnostou V, Wu J, Dhakal S, Wu M, Chen S, Feinberg T, Huang J, Saci A, Widlund HR, Fisher DE, Xiao Y, Rimm DL, Protopopov A, Wong KK, Chin L.

Nature. 2009 Jun 25;459(7250):1085-90. doi: 10.1038/nature08109.


High expression of mammalian target of rapamycin is associated with better outcome for patients with early stage lung adenocarcinoma.

Anagnostou VK, Bepler G, Syrigos KN, Tanoue L, Gettinger S, Homer RJ, Boffa D, Detterbeck F, Rimm DL.

Clin Cancer Res. 2009 Jun 15;15(12):4157-64. doi: 10.1158/1078-0432.CCR-09-0099. Epub 2009 Jun 9.


Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma.

Anagnostou VK, Syrigos KN, Bepler G, Homer RJ, Rimm DL.

J Clin Oncol. 2009 Jan 10;27(2):271-8. doi: 10.1200/JCO.2008.17.0043. Epub 2008 Dec 8.


Review. EGFR mutations in non-small cell lung cancer--clinical implications.

Charpidou A, Blatza D, Anagnostou V, Syrigos KN.

In Vivo. 2008 Jul-Aug;22(4):529-36. Review. Erratum in: In Vivo. 2008 Nov-Dec;22(6):886. Anagnostou, Elsa [corrected to Anagnostou, Valsamo].


Estrogen receptor co-activator (AIB1) protein expression by automated quantitative analysis (AQUA) in a breast cancer tissue microarray and association with patient outcome.

Harigopal M, Heymann J, Ghosh S, Anagnostou V, Camp RL, Rimm DL.

Breast Cancer Res Treat. 2009 May;115(1):77-85. doi: 10.1007/s10549-008-0063-9. Epub 2008 Jun 3.


Soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) detection in cancer patients: a prognostic marker for lung metastases from solid malignancies.

Karapanagiotou EM, Pelekanou E, Charpidou A, Tsaganos T, Anagnostou V, Plachouras D, Giamarellos-Bourboulis EJ, Syrigos KN.

Anticancer Res. 2008 Mar-Apr;28(2B):1411-5.


Right sited renal cell carcinoma metastasizing to the contralateral ovary: case report and review of the literature.

Anagnostou VK, Tiniakos DG, Chorti M, Kiagia M, Tourkantonis I, Alamara C, Syrigos KN.

Pathol Oncol Res. 2009 Mar;15(1):123-7. doi: 10.1007/s12253-008-9039-7. Epub 2008 May 21.


Epithelioid haemangioendothelioma of the lung presenting with pulmonary nocardiosis.

Anagnostou V, Mossa E, Mihas S, Lepouras A, Tiniakos DG.

In Vivo. 2007 Nov-Dec;21(6):1123-6.


Ontogeny of intrinsic innervation in the human thymus and spleen.

Anagnostou VK, Doussis-Anagnostopoulou I, Tiniakos DG, Karandrea D, Agapitos E, Karakitsos P, Kittas C.

J Histochem Cytochem. 2007 Aug;55(8):813-20. Epub 2007 Apr 16.


Using statins to reduce cardiovascular risk after carotid endarterectomy.

Floros G, Anagnostou V, Tsiga E, Ferenidou F, Papadimitriou D.

Evid Based Cardiovasc Med. 2006 Mar;10(1):1-4. Epub 2006 Feb 28. Review. No abstract available.


Ontogeny of intrinsic innervation in the human kidney.

Tiniakos D, Anagnostou V, Stavrakis S, Karandrea D, Agapitos E, Kittas C.

Anat Embryol (Berl). 2004 Nov;209(1):41-7.


Supplemental Content

Loading ...
Support Center